Tissue Plasminogen Activator in Thrombolytic Therapy



The book proceeds through a review of the biology, clinical pharmacology, and pharmacokinetics of tissue plasminogen activator with special attention to rt-PA, followed by a review of the clinical experience accumulated over the last 2 1/2 years in myocardial infarction, pulmonary embolism, venous thrombosis, and peripheral arterial occlusion.

Blood. 1988 Aug72(2):616-20. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Owen J(1), Friedman Thrombolytic medicines are approved for the emergency treatment of stroke and heart attack. The most commonly used drug for thrombolytic therapy is tissue plasminogen activator (tPA), but other drugs can do the same thing. A blood clot can block the arteries to the heart. Thrombolytic therapy Tissue plasminogen activator Pulmonary embolism 2 Indications for Systemic Treatment by Thrombolytic Agents in PE.Tissue Plasminogen Activators. This family of thrombolytic drugs is used in acute myocardial infarction, cerebrovascular thrombotic stroke and pulmonary embolism. Retaplase (Retavase) is a genetically engineered, smaller derivative of recombinant tPA that has increased potency and is faster acting than rtPA.Tissue plasminogen activator: a new thrombolytic agent. In the treatment of acute myocardial infarction, intravenous infusions of rt-PA appear to be moreSafety of thrombolytic therapy with urokinase or recombinant tissue plasminogen activator for peripheral arterial occlusion: a comprehensive compilation ofThrombolytic Therapy With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke. Where Do We Go From Here? A Cumulative Meta-Analysis.J Pediatr Surg. 1993 Oct28(10):1264-8 discussion 1268-9. Recombinant tissue plasminogen activator for neonatal and pediatric vascular thrombolytic therapy. Special Article from The New England Journal of Medicine Cost Effectiveness of Thrombolytic Therapy with Tissue Plasminogen Activator asJpn Heart J. 1996 Jan37(1):33-41. Accelerated ST-segment reduction after thrombolytic therapy with recombinant tissue plasminogen activator (rtPA) comparedThrombolytic therapy with streptokinase and tissue plasminogen activator in a patient with suspected acute myocardial infarction: A decision analysis.Thrombolytic Therapy With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke. Where Do We Go From Here? A Cumulative Meta-Analysis. delivery of tissue plasminogen activator for enhanced thrombolysis in activator (tPA) is the only FDA approved medical treatment for thePURPOSE: To evaluate the efficacy, safety, and results of direct thrombolytic therapy in intracranial dural sinus thrombosis by infusion of alteplase (recombinantThrombolytic Therapy Antithrombotic Dosing and Algorithms, Information. Tissue Plasminogen Activator- Derived by recombinant genetics from human DNA.Approved by the US Food and Drug Administration (FDA) in 1996 for treatment of AIS, intravenous rtPA (or alteplase) is the only thrombolytic agent approved forThrombolysis with recombinant tissue plasminogen activator and tirofiban in not eligible for thrombolytic treatment because of medical contraindications or